Hence, it is critically important to address whether the identification of EGFR alteration(s) and subsequent treatment with EGFR‐TKIs as part of curative‐intent treatment strategies affect the treatment outcome in patients with locally advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.